NASDAQ:APLT

Applied Therapeutics (APLT) Stock Price, News & Analysis

Applied Therapeutics logo
$0.10 0.00 (0.00%)
As of 11/6/2026

About Applied Therapeutics Stock (NASDAQ:APLT)

Advanced

Key Stats

Today's Range
$0.10
▼
$0.10
50-Day Range
$0.10
▼
$0.10
52-Week Range
$0.09
▼
$1.50
Volume
N/A
Average Volume
7.28 million shs
Market Capitalization
$15.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00
Consensus Rating
Reduce

Company Overview

Applied Therapeutics is a biotechnology company focused on developing small-molecule medicines for rare metabolic and other serious diseases. Founded in 2016, the company is based in New York and was founded by Shoshana Shendelman, who has served as its chief executive officer.

The company’s pipeline has centered on govorestat, an investigational inhibitor of the enzyme aldose reductase. Applied Therapeutics has studied the drug in conditions including classic galactosemia, SORD deficiency and PMM2-CDG, disorders that can affect multiple body systems and have limited treatment options.

Applied Therapeutics has also pursued drug development in other disease areas. Its programs are investigational; the company’s work has focused on clinical research and development rather than marketing an established portfolio of approved medicines.

AI Generated. May Contain Errors.

Applied Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

APLT MarketRank™: 
1.3170800056 of 5 stars

Applied Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 748th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Applied Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Applied Therapeutics has a consensus price target of $1.00, representing about 870.9% upside from its current price of $0.10.

  • Amount of Analyst Coverage

    Applied Therapeutics has received no research coverage in the past 90 days.

  • Read more about Applied Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Applied Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Applied Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Applied Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for APLT.
  • Dividend Yield

    Applied Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Applied Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Applied Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Applied Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.60% of the stock of Applied Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Applied Therapeutics' insider trading history.
Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APLT Stock News Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More Headlines

APLT Stock Analysis - Frequently Asked Questions

Applied Therapeutics' stock was trading at $0.10 at the start of the year. Since then, APLT shares have increased by 3.0% and is now trading at $0.1030.

Applied Therapeutics Inc. (NASDAQ:APLT) issued its quarterly earnings results on Thursday, November, 13th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The firm had revenue of $1 million for the quarter, compared to analysts' expectations of $250 thousand.

Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Viking Therapeutics (VKTX), Nikola (NKLAQ), AT&T (T) and NIO (NIO).

Company Calendar

Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:APLT
CIK
1697532
Fax
N/A
Employees
30
Year Founded
2017

Price Target and Rating

High Price Target
$1.00
Low Price Target
$1.00
Potential Upside/Downside
+870.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.62 million
Net Margins
N/A
Pretax Margin
-1,813.80%
Return on Equity
-340.84%
Return on Assets
-175.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.96
Quick Ratio
0.96

Sales & Book Value

Annual Sales
$1 million
Price / Sales
15.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.49 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
153,958,000
Free Float
151,495,000
Market Cap
$15.86 million
Optionable
Optionable
Beta
2.08

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:APLT) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners